SULLIVAN CHRISTOPHER RYAN (Interim CFO) sold 47.9% of their position (15.96K shares) of AVALO THERAPEUTICS, INC. on the open market
Open‑market sale worth $270.6K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 4/3/2026ACC: 0001810417-26-000006
Officer· Interim CFO
Since Apr 2020
-15.96K
Net shares
Net seller
$270.6K
Total sold
4
Open market trades
0B · 4S
4
Total transactions
15.96K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−500.00
Price / share
$15.86
Trade value
$7.93K
% of position
1.5%
4/1/2026
33.30K→32.80K
Common Stock
Direct
Shares
−7.48K
Price / share
$16.83
Trade value
$125.84K
% of position
22.8%
4/1/2026
32.80K→25.32K
Common Stock
Direct
Shares
−6.20K
Price / share
$17.02
Trade value
$105.55K
% of position
24.5%
4/2/2026
25.32K→19.12K
Common Stock
Direct
Shares
−1.78K
Price / share
$17.57
Trade value
$31.27K
% of position
9.3%
4/2/2026
19.12K→17.34K
Total
Net shares
−15.96K
Net value
-$270.59K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/1/2026 | S · Sale | −500.00 | $15.86 | $7.93K | 1.5% | 33.30K | 32.80K |
| Common Stock Direct | 4/1/2026 | S · Sale | −7.48K | $16.83 | $125.84K | 22.8% | 32.80K | 25.32K |
| Common Stock Direct | 4/2/2026 | S · Sale | −6.20K | $17.02 | $105.55K | 24.5% | 25.32K | 19.12K |
| Common Stock Direct | 4/2/2026 | S · Sale | −1.78K | $17.57 | $31.27K | 9.3% | 19.12K | 17.34K |
| Total | −15.96K | -$270.59K | ||||||
Derivative Transactions0
No derivative transactions reported